Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer

Abstract

It was concluded that PSA was better than PAP in evaluating patients before and after androgen-deprivation therapy. The nadir level of both markers was an important tool to predict progression-free survival in patients with metastatic prostatic cancer.